White River Junction, Vermont 05009

  • Depression


Veterans with treatment resistant depression (TRD) have the opportunity to receive transcranial magnetic stimulation (TMS) treatment via the VA's National TMS Clinical Pilot Program. While some see improvement with their depression, others do not. Therefore, it may be beneficial to be able to predict with biomarkers what participants may see improvement with their treatment. Electroencephalography (EEG) is a means to identify such biomarkers. Four hundred Veterans with TRD will be enrolled in this trial to determine whether neuroimaging biomarkers of repetitive transcranial magnetic stimulation (TMS) can be prospectively replicated in a large ecologically valid sample. Participants will have a total of EEG scans at baseline, every 5th treatment session, and at the end of treatment for a total of 7 EEG scans.

Study summary:

The goals of this study are to: (1) test a potential predictive resting EEG biomarker of antidepressant response (differential patters of gamma oscillations) in a large sample of Veterans with TRD receiving TMS (N=400); (2) assess whether a second putative biomarker (early changes in theta cordance during treatment) predict eventual response to TMS, as well as, leverage this large sample to identify other potential biomarkers (such as markers of early versus late response to TMS, markers of response to other TMS parameters (e.g., 5 Hz, 1 Hz or theta burst TMS), and markers of change with treatment that may speak to mechanism); and (3) create an infrastructure to rapidly identify and test additional EEG-based biomarkers of treatment response in patients with depression and other psychiatric conditions.


Inclusion Criteria: - Veterans participating in the VA TMS Pilot Program age 18 years or older - Able to provide written informed consent to participate in the EEG portion of this study and to allow linking such data to data collected as part of the TMS Pilot Program - Diagnosis of MDD based on DSM-5 criteria and be currently depressed despite prior treatment with at least one adequate antidepressant treatment - Receiving stable doses of psychiatric medications (no dose changes for >4 weeks prior to study entry), in stable psychotherapy, or receiving no psychiatric medications and/or psychotherapy Exclusion Criteria: - History of seizure disorder - Known structural or neurologic abnormalities present or close to the treatment site that would increase risk of seizure - History of brain surgery - History of recent traumatic brain injury (within 6 months) or any history of moderate to severe traumatic brain injury - Clinical evidence of severe or uncontrolled alcohol or substance use disorders within three months - Active withdrawal from alcohol or other substances of abuse - Implanted metal device in the head that would increase the risk of TMS - Metal in the head that would increase the risk of TMS - Current psychosis



Primary Contact:

Principal Investigator
Paul Holtzheimer, MD
White River Junction VA Medical Center, White River Junction, VT

Paul Holtzheimer, MD
Phone: (802) 295-9363 ext. 6042
Email: Paul.Holtzheimer@va.gov

Backup Contact:

Email: Techieh.Chen@va.gov
Techieh Chen
Phone: (802) 295-9363 ext. 6995

Location Contact:

White River Junction, Vermont 05009
United States

Paul Holtzheimer, MD
Phone: 802-295-9363
Email: Paul.Holtzheimer@va.gov

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: June 28, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.